{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-000675","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.904735+00:00","generated_at":"2026-05-28T07:32:13.213228+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Windtree shifts strategy to acquire FDA-approved product companies via all-stock deals","bullets":["New corporate strategy targets acquisition of small companies with FDA-approved products using equity.","Management aims to leverage commercialization expertise across large pharma and biotech to optimize acquired assets.","Company will continue advancing its cardiovascular and oncology pipeline alongside revenue-generating acquisitions.","CEO Jed Latkin says strategy marks a new chapter focused on near-term revenue and shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-000675","json":"https://secwatch.observer/filing/0001437749-25-000675.json","markdown":"https://secwatch.observer/filing/0001437749-25-000675.md","text":"https://secwatch.observer/filing/0001437749-25-000675.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774925000675/0001437749-25-000675-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774925000675/wint20250107_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T07:32:13.213228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}